Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Publication
, Journal Article
Czuczman, MS; Leonard, JP; Jung, S; Johnson, JL; Hsi, ED; Byrd, JC; Cheson, BD
Published in: Ann Oncol
November 1, 2018
Duke Scholars
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
November 1, 2018
Volume
29
Issue
11
Start / End Page
2271
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Czuczman, M. S., Leonard, J. P., Jung, S., Johnson, J. L., Hsi, E. D., Byrd, J. C., & Cheson, B. D. (2018). Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol, 29(11), 2271. https://doi.org/10.1093/annonc/mdx812
Czuczman, M. S., J. P. Leonard, S. Jung, J. L. Johnson, E. D. Hsi, J. C. Byrd, and B. D. Cheson. “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.” Ann Oncol 29, no. 11 (November 1, 2018): 2271. https://doi.org/10.1093/annonc/mdx812.
Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2018 Nov 1;29(11):2271.
Czuczman, M. S., et al. “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.” Ann Oncol, vol. 29, no. 11, Nov. 2018, p. 2271. Pubmed, doi:10.1093/annonc/mdx812.
Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann Oncol. 2018 Nov 1;29(11):2271.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
November 1, 2018
Volume
29
Issue
11
Start / End Page
2271
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis